Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have received a consensus recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and eleven have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $48.1250.

Several equities research analysts have issued reports on AVTX shares. HC Wainwright dropped their target price on shares of Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. Mizuho lifted their target price on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. Guggenheim began coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They set a “buy” rating and a $50.00 price target on the stock. Wolfe Research began coverage on shares of Avalo Therapeutics in a research note on Thursday, April 9th. They set an “outperform” rating and a $48.00 price target on the stock. Finally, BTIG Research lifted their price target on shares of Avalo Therapeutics from $40.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th.

Insiders Place Their Bets

In other Avalo Therapeutics news, CFO Christopher Ryan Sullivan sold 8,458 shares of Avalo Therapeutics stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $13.09, for a total transaction of $110,715.22. Following the transaction, the chief financial officer directly owned 8,880 shares of the company’s stock, valued at approximately $116,239.20. This trade represents a 48.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Paul Varki sold 75,063 shares of Avalo Therapeutics stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the transaction, the insider directly owned 3,634 shares in the company, valued at $73,297.78. This trade represents a 95.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 138,078 shares of company stock valued at $2,501,346. 4.46% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Bank of America Corp DE increased its stake in shares of Avalo Therapeutics by 3.5% in the first quarter. Bank of America Corp DE now owns 643,000 shares of the company’s stock worth $9,600,000 after buying an additional 21,650 shares during the period. Exome Asset Management LLC purchased a new position in shares of Avalo Therapeutics in the first quarter worth $2,379,000. Affinity Asset Advisors LLC increased its stake in shares of Avalo Therapeutics by 27.6% in the first quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after buying an additional 289,786 shares during the period. Renaissance Technologies LLC increased its stake in shares of Avalo Therapeutics by 556.4% in the first quarter. Renaissance Technologies LLC now owns 120,114 shares of the company’s stock worth $1,793,000 after buying an additional 101,814 shares during the period. Finally, Sei Investments Co. purchased a new position in shares of Avalo Therapeutics in the first quarter worth $849,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Price Performance

Shares of Avalo Therapeutics stock opened at $16.35 on Friday. Avalo Therapeutics has a 1 year low of $3.43 and a 1 year high of $24.27. The firm has a market cap of $859.52 million, a PE ratio of -2.99 and a beta of 0.78. The company has a 50 day simple moving average of $15.74 and a two-hundred day simple moving average of $16.40.

Avalo Therapeutics (NASDAQ:AVTX) last announced its earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.02. As a group, research analysts anticipate that Avalo Therapeutics will post -2.72 earnings per share for the current year.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.